ADAM9, His, Human

ADAM9, His, Human

A disintegrin and metalloproteinase 9 (ADAM9) is a member of the transmembrane ADAM family. It is expressed in different types of solid cancer and promotes tumor invasiveness. ADAM9 may be a prognostic marker for vestibular schwannomas (VS), and ADAM9 inhibition might have the potential as a systemic approach for the treatment of VS.
Z04994
¥65,734.00

Ask us a question
Product Introduction
Species Human
Protein Construction
ADAM9 (Ala29-Asp697)
Accession # Q13443-1		 His
N-term C-term
Purity > 95% as determined by Bis-Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its ability to cleave a fluorogenic peptide substrate Mca­PLAQAV­Dpa­RSSSR­NH2. Test result meets the standard.
Expression System HEK293
Theoretical Molecular Weight 77.95 kDa
Apparent Molecular Weight Due to furin cleavage site, the mature form migrates to 40-45 kDa and 60-70 kDa based on Bis-Tris PAGE result.
Formulation Supplied as 0.22μm filtered solution in 50mM Tris, 500mM NaCL, 0.005% Brij-35, 20% Glycerol (pH 8.5).
Concentration Verified by one or more methods from A280/Bioactivity/BCA/Bradford.
Storage & Stability This product remains stable for 6 months at -80°C or below. Avoid repeated freeze-thaw cycles.

Background
Target Background A disintegrin and metalloproteinase 9 (ADAM9) is a member of the transmembrane ADAM family. It is expressed in different types of solid cancer and promotes tumor invasiveness. ADAM9 may be a prognostic marker for vestibular schwannomas (VS), and ADAM9 inhibition might have the potential as a systemic approach for the treatment of VS.
Synonyms ADAM 9; Meltrin-gamma; Mdc9; Mltng; Adam9; Kiaa0021; AU020942; MDC9; mKIAA0021; CORD9; MCMP; MLTNG

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.